Related Experiment Video
Updated: May 24, 2025

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
Transition from preclinical to clinical application of CTLA4-Ig co-stimulation blockage in beta-cell replacement
Quentin Perrier1, Johan Noble2, Sandrine Lablanche3
1Univ. Grenoble Alpes, INSERM U1055 LBFA, Pharmacy department, Grenoble Alpes University Hospital, Grenoble, France.
Abstract:
Beta-cell replacement therapies, including islet and pancreas transplantation, offer promising results in term of glycemic control for patients with type 1 diabetes experiencing high glycemic variability and severe hypoglycemia. However, long-term insulin independence remains challenging due to progressive graft function decline. Immunosuppressive regimens, especially calcineurin inhibitors such as tacrolimus, are known to be diabetogenic, contributing to the paradox of impaired beta-cell function in a diabetes treatment setting. Recent studies have focused on CTLA4-Ig (e.g., belatacept) as a potential alternative to calcineurin inhibitors, showing promising results in preclinical and clinical models. This review summarizes key advancements and remaining challenges in CTLA4 applications for beta-cell replacement. First, genetic engineering approaches aiming for CTLA4 expression in islets demonstrated initial success in delaying rejection but remain hindered by immune escape and limited integration efficacy. Coating techniques and exogenous CTLA4-Ig administration offer simpler, albeit transient, immunosuppressive effects, which, combined with encapsulation technologies, can improve graft survival. In non-human primate models, islet transplantation with immunosuppressant regimen using CTLA4-Ig combined with agents such as sirolimus or anti-CD154 has shown extended insulin independence, though full immune tolerance remains elusive. A limited number of human studies using belatacept for beta-cell replacement indicate reduced HbA1c levels and avoidance of severe hypoglycemia, yet consistent absence of rejection remains unachieved. Future research on BCR with CTLA4-Ig should explore graft survival in human islets transplantation and refine immunosuppressive protocols to leverage CTLA4-Ig potential in improving long-term graft function, thus enhancing the sustainability of CTLA4-Ig in clinical beta-cell replacement approach.
Insights
CTLA4-Ig shows promise for type 1 diabetes treatment by improving beta-cell replacement therapies. While challenges remain, this approach offers potential for long-term insulin independence and better glycemic control.
Area of Science:
- Immunology
- Endocrinology
- Transplantation Science
Background:
- Beta-cell replacement therapies like islet and pancreas transplantation improve glycemic control in type 1 diabetes.
- Long-term success is limited by graft function decline and diabetogenic immunosuppressants (e.g., tacrolimus).
- CTLA4-Ig (e.g., belatacept) is explored as a safer alternative to calcineurin inhibitors.
Purpose of the Study:
- To review advancements and challenges of CTLA4-Ig in beta-cell replacement therapy.
- To assess CTLA4-Ig's potential in improving graft survival and long-term function.
- To highlight future research directions for CTLA4-Ig in clinical applications.
Main Methods:
- Review of genetic engineering, coating techniques, and exogenous administration of CTLA4-Ig.
- Analysis of preclinical (non-human primate) and clinical studies.
- Evaluation of combination therapies with CTLA4-Ig (e.g., sirolimus, anti-CD154).
Main Results:
- Genetic engineering showed initial success but faced immune escape and integration issues.
- Coating and exogenous CTLA4-Ig with encapsulation improved graft survival transiently.
- Non-human primate studies demonstrated extended insulin independence with CTLA4-Ig combinations.
- Limited human studies showed reduced HbA1c and hypoglycemia but not consistent rejection absence.
Conclusions:
- CTLA4-Ig holds significant potential for beta-cell replacement therapies in type 1 diabetes.
- Further research is needed to optimize graft survival and immunosuppressive protocols for long-term efficacy.
- Refining CTLA4-Ig strategies is crucial for sustainable clinical beta-cell replacement.
More Related Videos
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
16:26Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007